NeuPath Health Inc (NPTH) Fair Value & Analysis
Healthcare · CA · Market cap C$34.3M
Fair value as of: Jul 19, 2026
From 14 valuation models · updated 23 days ago
Fair value updated Jul 19, 2026, revised from C$1.05 to C$0.5900 (−43.8%) since Jun 24, 2026. Share price −6.3% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from C$0.4300 (bear) to C$0.7400 (bull), base C$0.5900. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 57/100 (solid quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
60‑month range C$0.0800 – C$0.7100 · fair‑value band C$0.4300 – C$0.7400 · the C$0.5900 price screens below the C$0.5900 fair value. Dashed = 300-day average. As of Jul 19, 2026.
Analysis
NeuPath Health Inc (NPTH) currently trades at C$0.5900, while our model-based Fair Value estimate is C$0.5900, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Trailing-twelve-month revenue stands at C$89.4M. Revenue grew 11.2% year over year. It earns a return on equity of 1.4%. Net debt stands at C$1.7M. Fundamentals as of Jul 19, 2026
Our scenario range runs from C$0.4300 (bear case) to C$0.7400 (bull case); at C$0.5900, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 13% below its 52-week high and 157% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at 0%, NPTH screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: DCF Models (C$0.6300) versus Earnings-Based (C$0.2400). Highest evidence: Growth DCF (80).
Notify me when NPTH reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 66
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
NeuPath Health Inc. provides chronic pain management services in Canada. It operates a network of medical clinics in Ontario and Alberta that offer assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports-related injuries, and concussions.
Full company description
NeuPath Health Inc. provides chronic pain management services in Canada. It operates a network of medical clinics in Ontario and Alberta that offer assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports-related injuries, and concussions. The company also provides workplace health services and independent medical assessments to employers and disability insurers, as well as legal practices through a network of health care providers comprising cardiologists, dentists, dermatologists, psychiatrists, endocrinologists, gastroenterologists, general practitioners, internal medicine specialists, neurologists, neuropsychiatrists, neuropsychologists, occupational therapists, ophthalmologists, orthopedic surgeons, physiatrists, physiotherapists, psychologists, respirologists, and rheumatologists. In addition, it operates a network of healthcare clinics and related businesses. The company is headquartered in Mississauga, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
NeuPath Health Inc reported revenue of C$87.2M in FY2025 versus C$60.9M in FY2021, a compound +9.4%/yr. Reported net income was −C$717K in FY2025.
Watch NPTH: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare NeuPath Health Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is NeuPath Health Inc (NPTH) overvalued or undervalued?
What is the fair value of NPTH?
What is the quality score of NPTH?
What is the revenue of NeuPath Health Inc (NPTH)?
What is the net profit margin of NPTH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track NeuPath Health Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.